License: Exclusive license to dry powder formulation of treprostinilĬapital: $45M upfront + $50M in milestonesĭeal: Private Offering of Common Shares (ADS)Ĭompany: Adaptimmune Therapeutics (Nasdaq: ADAP – Oxford, UK) Licensor: Mannkind (Nasdaq: MNKD – Westlake Village, CA) Licensee: United Therapeutics (Nasdaq: UTHR – Silver Spring, MD) License: Rights to AZD3241, an oral myeloperoxidase (MPO) inhibitor for the treatment of multiple system atrophy (MSA) Licensor: AstraZeneca (NYSE: AZN – Cambridge, UK) Licensee: Biohaven Pharmaceutical (NYSE : BHVN – New Haven, CT) Underwriters: BofA Merrill Lynch, Leerink Partners, Wells Fargo Securities, Baird One (14.25%), Morgenthaler Ventures Partners IX (13.29%), Sofinnova Venture Partners VIII (10.61%), Baker Bros. Major Investors pre-IPO: New Leaf Venture Partners (14.25%), OrbiMed Private Investments IV (14.25%), S.R. Morgan, Morgan Stanley, Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez & Co., The Williams Capital GroupĬompany: Principia Biopharma (South San Francisco, CA)Īrea: Autoimmune diseases, oncology, inflammationĬapital Planned to Raise: $80.86M – $91.64M Major Investors pre-IPO: Eli Lilly (100%) Underwriters: Morgan Stanley, BofA Merrill Lynch, Barclays, ChardanĬompany: Elanco Animal Health (Greenfield, IN)Ĭapital Planned to Raise: $1,446.7M – $1,663.7M Advisors, Victor Perlroth (23.7%), Stephen Charles (9.8%), Dustin A. Sources: FiercePharma Press release BioPharma Diveīuyer: Zealand Pharma (CSE: ZEAL, and Nasdaq: ZEAL – Copenhagen, Denmark)Īsset: Royalty rights to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide Seller: Novartis (NYSE: NVS – Basel, Switzerland)Īsset: Sandoz US dermatology business and 300 generic US productsĪggregate purchase price: $900M cash + $100M potential earnout Investors: S2G Ventures, Continental Grain Company, and Middleland Capitalīuyer: Aurobindo Pharma (NSE: AUROPHARMA – Hyderabad, India) It has, however, notably only taken external capital in recent years.The week in numbers (the total value of the operations is shown in parenthesis):Īngels, VC, PE, CVC deals: 20 ($526.05+M)Īrea: Satellite imagery and machine learning softwareĪrea: Digital agriculture technology provider Today, the HighRadius platforms for order-to-cash and treasury management help more than 600 clients, including more than 200 of the Forbes Global 2000, “optimize their working capital.”įounded in 2006, HighRadius may not technically be a “startup” in the literal sense of the word. HighRadius said it will use the new capital “to fuel product innovation and expand global go-to-market reach.”Īt the beginning of 2020, HighRadius had more than 400 customers, including over 200 of the Forbes Global 2000 such as Walmart, Nike and Procter & Gamble, and claimed to process more than $1 trillion in transactions per year. With this latest financing, HighRadius has raised $475 million in funding.Įxisting backers ICONIQ Growth and Susquehanna Growth Equity also participated in the round along with a slew of high-profile CEOs, including Snowflake Chairman and CEO Frank Slootman Snowflake CFO Michael Scarpelli Procore Technologies CEO Tooey Courtemanche and Airtable co-founder and CEO Howie Liu. The round values Houston-based HighRadius at $3.1 billion, triple its valuation of “more than $1 billion” at the time of its $125 million Series B in January of 2020. HighRadius, which has developed AI-powered fintech software, announced Tuesday it has raised $300 million in a Series C funding round led by D1 Capital and Tiger Global.
0 kommentar(er)
